Skip to content
DataLookout
Menu

NCT07889102

Impact of Telepharmacy on Hemodialysis Outcomes

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in hemoglobin (Hb) level
Timeframe: 5 months

Secondary (1)

Change in erythropoietin dose

Arms and interventions

Standard Care Control GroupActive comparator

Participants assigned to this arm received routine hemodialysis care according to standard clinical practice without additional telepharmacy support. This included regular physician follow-up, laboratory monitoring, and medication management as determined by the treating healthcare team. No structured pharmacist-led remote monitoring or scheduled telecommunication-based interventions were provided.

Telepharmacy Intervention GroupExperimental

Participants assigned to this arm received routine maintenance hemodialysis care in addition to a structured telepharmacy intervention delivered by trained clinical pharmacists over a 5-month period. The intervention included scheduled telephone follow-up, medication review, adherence assessment, individualized counseling, monitoring of laboratory results, identification and resolution of drug-related problems, and collaboration with treating physicians to optimize erythropoiesis-stimulating agent (ESA) therapy and overall medication management.

Other: Routine Standard Care

Behavioral: Telepharmacy Intervention

Sites

2 sites in 1 country